XOMA Royalty Corporation (XOMA)
NASDAQ:XOMA
Want to see XOMA full AI Analyst Report?
XOMA Stock Chart & Stats
$39.71
$0.08(0.31%)
At close: 4:00 PM EST
$39.71
$0.08(0.31%)
Day’s Range― - ―
52-Week Range$22.29 - $42.81
Previous CloseN/A
Volume8.24K
Average Volume (3M)53.64K
Market Cap
$738.79M
Enterprise Value$553.36M
Total Cash (Recent Filing)$94.96M
Total Debt (Recent Filing)$124.73M
Price to Earnings (P/E)15.8
Beta1.44
Next Earnings
Jul 30, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.65
Shares Outstanding17,678,741
10 Day Avg. Volume49,949
30 Day Avg. Volume53,642
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)4.60
Price to Sales (P/S)9.17
P/FCF Ratio166.54
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue15.27
Enterprise Value/Gross Profit16.37
Enterprise Value/Ebitda11.03
Forecast
1Y Price Target
$39.00Price Target Upside-1.79% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.79
Revenue Forecast (FY)$60.73M
Bulls Say, Bears Say
Bulls Say
Royalty-based Business ModelA royalty and milestone model transfers commercialization and manufacturing risk to third parties while delivering recurring, low-capex cashflows. This structure supports durable revenue streams, scalable portfolio growth through acquisitions, and predictable long-term cash generation if underlying drugs maintain sales.
Improved Profitability And Cash GenerationReturn to sustained net income and positive free cash flow indicates the business can convert royalties and milestones into distributable cash. That enabled buybacks and supports capital actions (e.g., preferred redemption), increasing financial flexibility and strengthening the firm's ability to fund new royalty purchases over the medium term.
Expanding, Diversified Royalty PortfolioActive portfolio expansion and partnerships broaden therapeutic and phase exposure, reducing idiosyncratic risk from any single asset. Multiple registrational programs and recent acquisitions increase the probability of future royalty streams and milestone events, supporting more stable, diversified long-term cash flow.
Bears Say
Elevated LeverageSustained debt levels above equity constrain financial flexibility, raise interest obligations, and amplify downside in periods with weaker royalty receipts. High leverage may limit capacity to buy new assets, fund opportunistic growth, or absorb missed milestones without additional financing or asset sales.
Historical Cash-flow And Revenue VolatilityReliance on milestone timing and uneven royalty receipts has produced multi-year swings in cash flow and revenue, making earnings quality variable. Such volatility complicates forecasting, capital allocation and the sustainable conversion of reported profits into repeatable free cash flow over the medium term.
Counterparty And Transaction Execution RiskBusiness outcomes depend heavily on third-party developers and legal outcomes; the proposed merger and CVR expose shareholders to regulatory, integration and litigation uncertainties. Execution risk and dependence on counterparties' commercialization success create persistent downside if approvals delay or litigation yields no proceeds.
XOMA Royalty Corporation News
XOMA FAQ
What was XOMA Royalty Corporation’s price range in the past 12 months?
XOMA Royalty Corporation lowest stock price was $22.29 and its highest was $42.81 in the past 12 months.
What is XOMA Royalty Corporation’s market cap?
XOMA Royalty Corporation’s market cap is $738.79M.
When is XOMA Royalty Corporation’s upcoming earnings report date?
XOMA Royalty Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 45 days.
How were XOMA Royalty Corporation’s earnings last quarter?
XOMA Royalty Corporation released its earnings results on Apr 30, 2026. The company reported $0.168 earnings per share for the quarter, beating the consensus estimate of $0.128 by $0.04.
Is XOMA Royalty Corporation overvalued?
According to Wall Street analysts XOMA Royalty Corporation’s price is currently Overvalued.
Does XOMA Royalty Corporation pay dividends?
XOMA Royalty Corporation does not currently pay dividends.
What is XOMA Royalty Corporation’s EPS estimate?
XOMA Royalty Corporation’s EPS estimate is 0.18.
How many shares outstanding does XOMA Royalty Corporation have?
XOMA Royalty Corporation has 17,678,741 shares outstanding.
What happened to XOMA Royalty Corporation’s price movement after its last earnings report?
XOMA Royalty Corporation reported an EPS of $0.168 in its last earnings report, beating expectations of $0.128. Following the earnings report the stock price went down -0.122%.
Which hedge fund is a major shareholder of XOMA Royalty Corporation?
Currently, no hedge funds are holding shares in XOMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
XOMA Royalty Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$39.00 (-1.79% Downside)
$39.00 (-1.79% Downside)
Hedge Fund Trend
Increased
By 377.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.28%
12-Months-Change
Fundamentals
Return on Equity
30.21%
Trailing 12-Months
Asset Growth
27.78%
Trailing 12-Months
Company Description
XOMA Royalty Corporation
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.
XOMA Company Deck
XOMA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and financial story: substantial year-over-year revenue and royalty growth, a large and diversified expansion of the royalty portfolio, positive GAAP net income and operating cash flow, meaningful liquidity ($≈83M), and shareholder returns via buybacks. Offsetting risks include recent Phase III clinical setbacks, ongoing litigation with uncertain outcomes and associated costs, some reliance on non-cash GAAP gains, and interest and cash outflows that reduced unrestricted cash modestly. Overall, the company portrays momentum toward an inflection point where royalties may cover operating costs, but execution risks from development-stage assets and litigation remain.View all XOMA earnings summariesXOMA Stock 12 Month Forecast
Average Price Target
$39.00
▼(-1.79% Downside)
Technical Analysis
Ocugen
―
Corvus Pharmaceuticals
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
10.69% Insiders
13.45% Mutual Funds
24.30% Other Institutional Investors
45.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---